Anne-Grete Märtson
Assistant professor
- Naam
- Dr. A. Märtson
- Telefoon
- +31 71 527 6211
- a.martson@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0001-6478-1959
Meer informatie op de Engelstalige pagina.
Assistant professor
- Wiskunde en Natuurwetenschappen
- Leiden Academic Centre for Drug Research
- LACDR/Pharmacology
- Martson A., da Silva Ferreira A.R., Veringa A., Liu L., Wardill H.R., Junier L.A.T., Werf T.S. van der, Harmsen H.J.M., Sturkenboom M.G.G., Span L.F., Tissing W.J.E. & Alffenaar J.C. (2023), Exposure of anti-infective drugs and the dynamic changes of the gut microbiota during gastrointestinal mucositis in autologous stem cell transplant patients: a pilot study, Annals of Hematology 102(2): 421-427.
- Venuti F., Trunfio M., Märtston A., Lipani F., Audagnotto S., Di Perri G. & Calcagno A. (2023), Extended and continuous infusion of novel protected β-lactam antibiotics: a narrative review, Drugs 83(11): 967-983.
- Stott K.E., Moyo M., Ahmadu A., Kajanga C., Gondwe E., Chimang'anga W., Chasweka M., Leeme T.B., Molefi M., Chofle A., Bidwell G., Changalucha J., Unsworth J., Jimenez-Valverde A., Lawrence D.S., Mwandumba H.C., Lalloo D.G., Harrison T.S., Jarvis J.N., Hope W. & Märtson A. (2023), Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis, Journal of Antimicrobial Chemotherapy 78(1): 276-283.
- Born D.A. van den, Märtson A., Veringa A., Punt N.C., Werf T.S. van der, Alffenaar J.W.C., Sturkenboom M.G.G. & Touw D.J. (2023), Voriconazole exposure is influenced by inflammation: a population pharmacokinetic model, International Journal of Antimicrobial Agents 61(4): 106750.
- Pignatti P., Visca D., Loukides S., Märtson A., Alffenaar J.C., Migliori G.B. & Spanevello A. (2022), A snapshot of exhaled nitric oxide and asthma characteristics: experience from high to low income countries, Pulmonology 28(1): 44-58.
- Kulkarni P., Harsulkar A., Märtson A., Suutre S., Märtson A. & Koks S. (2022), Mast cells differentiated in synovial fluid and resident in osteophytes exalt the inflammatory pathology of osteoarthritis, International Journal of Molecular Sciences 23(1): 541.
- Grit G.F., Märtson A., Knoester M., Toren-Wielema M.L. & Touw D.J. (2022), Shedding a light on acyclovir pharmacodynamics: a retrospective analysis on pharmacokinetic/pharmacodynamic modelling of acyclovir for the treatment of varicella zoster virus infection in immunocompromised patients: a pilot study, Pharmaceutics 14(11): 2311.
- Kim H.Y., Byashalira K.C., Heysell S.K., Märtson A., Mpagama S.G., Rao P., Sturkenboom M.G.G. & Alffenaar J.C. (2022), Therapeutic drug monitoring of anti-infective drugs: implementation strategies for 3 different scenarios, Therapeutic Drug Monitoring 44(1): 3-10.
- Kim H.Y., Baldelli S., Märtson A., Stocker S., Alffenaar J.W., Cattaneo D. & Mariott D.J.E. (2022), Therapeutic drug monitoring of the echinocandin antifungal agents: is there a role in clinical practice? A position statement of the anti-infective drugs committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology, Therapeutic Drug Monitoring 44(1): 198-214.
- Märtson A. & Alffenaar J. C. (2021), Investigator-initiated studies in infectious diseases: considerations for pharmacokinetic-pharmacodynamic optimization, Clinical Infectious Diseases 73(9): 1742.
- Märtson A., Sturkenboom M.G.G., Knoester M., Werf T.S. van der, Alffenaar J.C. & Hop W. (2021), Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads, Journal of Antimicrobial Chemotherapy 77(2): 466-473.
- Märtson A., Edwina A.E., Kim H.Y., Knoester M., Touw D.J., Sturkenboom. M.G.G. & Alffenaar J.C. (2021), Therapeutic drug monitoring of ganciclovir: where are we?, Therapeutic Drug Monitoring 44(1): 138-147.
- da Silva Ferreira A.R., Märtson A., Boer A. de, Wardill H.R., Alffenaar J., Harmsen H.J.M. & Tissing W.J.E. (2021), Does chemotherapy-induced gastrointestinal mucositis affect the bioavailability and efficacy of anti-infective drugs?, Biomedicines 9(10): 1389.
- Wicha S.G., Märtson A., Nielsen E.I., Koch B.C.P., Friberg L.E., Alffenaar J. & Minichmayr I.K. (2021), From therapeutic drug monitoring to model‐informed precision dosing for antibiotics, Clinical Pharmacology & Therapeutics 109(4): 928-941.
- Märtson A., Edwina A.E., Burgerhof J.G.M., Berger S.P., Joode A. de, Damman K., Verschuuren E.A.M., Blokzijl H., Bakker M., Span L F., Werf T.S. van der, Touw D.J., Sturkenboom M.G.G., Knoester M. & Alffenaar J.W.C. (2021), Ganciclovir therapeutic drug monitoring in transplant recipients, Journal of Antimicrobial Chemotherapy 76(9): 2356-2363.
- Märtson A. & Alffenaar J.C. (2021), Investigator-initiated studies in infectious diseases: considerations for pharmacokinetic-pharmacodynamic optimization, Clinical Infectious Diseases 73(9): 1742.
- Sturkenboom M.G.G., Märtson A., Svensson E.M., Sloan D.J., Dooley K.E., Elsen S.H.J. van den, Denti P., Peloquin C A., Aarnoutse R.E. & Alffenaar J.C. (2021), Population pharmacokinetics and Bayesian dose adjustment to advance TDM of anti-TB Drugs, Clinical Pharmacokinetics 60(6): 685-710.
- Alffenaar J., Märtson A., Heysell S.K.., Cho J., Patanwala A., Burch G., Kim H.Y., Sturkenboom M.G.G., Byrne A., Marriott D., Sandaradura I., Tiberi S., Sintchencko V., Srivastava S. & Peloquin C.A. (2021), Therapeutic drug monitoring in non-tuberculosis mycobacteria infections, Clinical Pharmacokinetics 60(6): 711-725.
- Märtson A., Elst K.C.M. van der, Veringa A., Zijlstra J.G., Beishuizen A., Werf T.S. van der, Kosterink J.G.W., Neely M. & Alffenaar J. (2020), Caspofungin weight-based dosing supported by a population pharmacokinetic model in critically ill patients, Antimicrobial Agents and Chemotherapy 64(9): e00905-20.
- Abu-Raya B., Migliori G.B., O'Ryan M., Edwards K., Torres A., Alffenaar J., Märtson A., Centis R., D'Ambrosio L., Flanagan K., Hung I., Lauretani F., Leung C.C. Leuridan E. Maertens K., Maggio M.G., Nadel S., Hens N., Niesters H., Osterhaus A., Pontali E., Principi N., Rossato S.D., Omer S., Spanevello A., Sverzellati N., Tan T., Torres-Torreti J.P., Visca D. & Esposito S. (2020), Coronavirus disease-19: an interim evidence synthesis of the world association for infectious diseases and immunological disorders (WAIDID), Frontiers in Medicine 7: 572485.
- Ong C.W.M., Migliori G.B., Raviglione M., MacGregor-Skinner G., Sotgiu G., Alffenaar J., Tiberi S., Adlhoch C., Alonzi T., Archuleta S., Brusin S., Cambau E., Capobianchi M.R., Castilletti C., Centis R., Cirillo D.M., D'Ambrosio L., Delogu G., Esposito S.M.R., Figueroa J., Friedland J.S., Ho B.C H., Ippolito G., Jankovic M., Kim H. Y., Rosales K. S., Ködmön C., Lalle E., Leo Y. S., Leung C., Märtson A., Melazzini M.G., Najafi F.S., Penttinen P., Petrone L., Petruccioli E., Pontali E., Saderi L., Santin M., Spanevello A., Crevel R. van, Werf M.J. van der, Visca D., Viveiros M.,Zellweger J., Zumla A. & Goletti D. (2020), Epidemic and pandemic viral infections: impact on tuberculosis and the lung: a consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC), European Respiratory Journal 56(4): 2001727.
- Al-Shaer M.H., Märtson A., Alghamdi W.A., Alsultan A., An G., Ahmed S., Alkabab Y., Banu S., Houpt E.R., Ashkin D., Griffith D.E., Cegielski J.P., Heysell S.K. & Peloquin C.A. (2020), Ethionamide population pharmacokinetic model and target attainment in multidrug-resistant tuberculosis, Antimicrobial Agents and Chemotherapy 64(9): e00713-20.
- Märtson A., Bakker M., Blokzijl H., Verschuuren E.A.M., Berger S.P., Span L.F.R., Werf T.S. van der & Alffenaar J.C. (2020), Exploring failure of antimicrobial prophylaxis and pre-emptive therapy for transplant recipients: a systematic review, BMJ Open 10: e034940.
- Kim H.Y., Märtson A., Dreesen E., Spriet I., Wicha S.G., McLachlan A.J. & Alffenaar J. (2020), Saliva for precision dosing of antifungal drugs: saliva population pk model for voriconazole based on a systematic review, Frontiers in Pharmacology 11: 894.
- Märtson A., Burch G., Ghimire S., Alffenaar J.C. & Peloquin C.A. (2020), Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems, Expert Opinion on Drug Metabolism & Toxicology 17(1): 23-39.
- Märtson A., Touw D., Damman K., Bakker M., Oude L.A., Werf T. van der, Knoester M. & Alffenaar J.C. (2019), Ganciclovir therapeutic drug monitoring: a case series, Therapeutic Drug Monitoring 41(2): 107-110.
- Märtson A., Veringa A., Heuvel E.R. van den, Bakker M., Touw D.J., Werf T.S. van der, Span L.F.R. & Alffenaar J.C. (2019), Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations, Mycoses 62(8): 698-705.
- Märtson A., Veringa A., Bakker M., Heuvel E.R. van den, Touw D.J., Werf T.S. van der, Span L.F.R. & Alffenaar J.C. (2019), Posaconazole trough concentrations are not influenced by inflammation: a prospective study, International Journal of Antimicrobial Agents 53(3): 325-329.